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Background: After the recent outbreak of foot-and-mouth disease (FMD) in Korea, a vaccination policy has been
applied to control the disease. In addition, several non-specific immune stimulators have been used without any
scientific evidence that they would enhance the immune response after FMD vaccination and/or protect against
FMD. Based on the current situation, the aim of this study was to evaluate the effect of the non-specific immune
stimulator germanium biotite on FMD vaccination and immune responses in cattle. To achieve our goal, immune
responses to FMD vaccination, such as levels of IgG and IgA, antibody duration, and virus-neutralizing titers were
investigated after germanium biotite feeding. The PBMC typing and proliferative response after stimulation with
mitogens, the cytokines expression level of PBMC, and the lysozyme activity in the serum were measured to
evaluate the immune enhancing effects of germanium biotite following its administration.
Results: Following the first vaccination, high level of IgG (at 4 weeks) and IgA (at 2 and 31 weeks) titers in serum
and saliva were observed in the germanium biotite-feeding group (p < 0.05). The germanium biotite group also
showed high and longstanding inhibition percentage value in ELISA assay at 31 weeks (p < 0.05). Generally, higher
virus-neutralizing antibody titers were observed in the feeding group at 20 and 31 weeks after vaccination. Following
the feeding germanium biotite, the germanium biotite group showed increased subpopulation of CD4+ lymphocytes
and MHC I+II+ cells in PBMCs at 23 week, responding to stimulation of ConA. The levels of IFN-γ (at 3 and 8 weeks),
IL-1α (at 3, 11, and 23 weeks), IL-1β (at 3, 8, and 11 weeks), and IL-4 (at 8 and 11 weeks) gene expression were also
significantly increased in the feeding group (p < 0.01 and p < 0.05). Feeding with germanium biotite increased the
lymphocytes’ proliferative response to the stimulation of ConA and LPS at 23 weeks and lysozyme activity at 9 weeks
after feeding.
Conclusions: These results suggest that germanium biotite feeding could increase the protection against FMD virus
infection via the induction of higher humoral and cellular immune responses in cattle.
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Foot-and-mouth disease (FMD) is a highly contagious
and economically important disease that affects cloven-
hoofed animals, and it is characterized by appetite loss,
an increase in body temperature, and vesicles in the
mouth, tongue, hooves, and nipples [1,2]. The disease is
caused by the FMD virus (FMDV), which is a small,
icosahedral, non-enveloped RNA virus classified within
the Aphthovirus genus as a member of Picornaviridae.
The clinical severity of the disease varies with the strain
of FMDV, infection dose, species, and individual suscep-
tibility of the host [3]. The disease can be transmitted
via direct or indirect contact between FMDV-infected
animals and susceptible animals [2].
Due to its high mutation rate, this virus exists as seven
distinct serotypes (O, A, C, Asia 1, South African territor-
ies [SAT]1, SAT2, and SAT3) as well as numerous and
constantly evolving subtypes, which shows a spectrum of
antigenic diversity [2,3]. Therefore, one major problem in
controlling FMD is antigenic variation, as infection or vac-
cination with one FMDV serotype does not protect against
other serotypes, and it may even fail to protect fully
against other subtypes within the same serotype [4-6].
This problem has been raised by the experimental and
field data of previous researchers on vaccination, including
both single and multivalent vaccines [3,7,8].
Despite the powerful effects of vaccines, which have
mitigated enormous FMD outbreaks, the current vaccines
have many problems to overcome such as the long time
required to induce antibodies and short duration of im-
munity when applying them to emergency and routine
vaccination programs [6-9]. Therefore, strategies to im-
prove the immune response to vaccination have included
using higher vaccine doses or increasing the number of
doses, using different routes of administration, accelerat-
ing the dosing schedule, and using adjuvants such as anti-
gen delivery systems and various immunostimulators [10].
The immune response against FMDV is related to circu-
lating humoral antibody titers; this is considered the most
important factor in conferring protection against FMD
[4]. The importance of cell-mediated immunity also has
been recognized in the induction of humoral immunity
and the clearance of FMDV. T-cell responses mediated by
CD4+ cells are required for protective immunity against
FMDV as they participate in the production of antiviral
antibodies [11]. Subsets of the CD4+ major histocompati-
bility complex (MHC) class II-restricted T-cells respond
to activation by antigen-presenting cells and antigens by
producing a T helper type 1 (Th1, IFN-γ) and T helper
type 2 (Th2; IL-4, IL-5, and IL-13) responses [12]. Several
studies have also demonstrated the presence of FMD-
specific MHC II-restricted responses in cattle and pigs
[11-13]. The antiviral responses of CD8+ T-cells were also
detected following FMDV infection in previous studies[14,15]. These antiviral responses were through direct
cytotoxicity or release of cytokines such as IFN-γ following
vaccination, and that the antiviral responses were almost
100 times higher following re-stimulation [15]. MHC class
I-restricted CD8+ T-cells also showed specific immune re-
sponse to FMDV as memory cells; however, the correlation
between FMDV-specific CD8+ T-cell recognition and pro-
tection remains to be defined [14,15]. In addition, the in-
nate immune systems, as well as adaptive immune, play an
important role in immune responses to FMDV infection
[16,17]. The innate immune system, characterized by non-
specific responses, is associated with early protection
against FMD and is involved in the formation of adaptive
immune response to FMDV infection [16,17].
Germanium biotite, as a well-known feed supplement, is
a common phyllosilicate mineral that contains potassium,
magnesium, iron, aluminum, and silicate. It has been re-
ported that the effects of non-specific immune stimulating
of biotite are associated with the immune cells being stim-
ulated by silicates [18-20]. Fibrogenic silicates (SiO2) acti-
vated proinflammatory macrophages, and aluminosilicates
(Al2SiO5) improved immune-cell differentiation [21]. Alu-
minosilicates act as a nonspecific immunostimulator that
is similar to a superantigen [22]. Superantigens are a class
of extremely potent T-cell mitogens, and have a high affin-
ity to regions of MHC II molecules [23]. Indeed, proin-
flammatory macrophages, which belong to MHC class II
antigen–presenting cells, are activated by fibrogenic sili-
cate particulates [21]. Thus, previous studies have sug-
gested that germanium biotite has a potential as a new
supplement for immunostimulators, prophylactic agents,
and remedial agents [20].
Since the devastating FMD outbreak in Korea at the end
of 2010, cattle, pigs, and some small ruminants have been
vaccinated with a trivalent FMD vaccine (O1 Manisa, A
Malaysia 97, and Asia1 Shamir) at least 6 protective dose
50% (PD50). [24]. To improve the vaccine efficacy, several
non-specific immune stimulators have been used in Korea
without any scientific understanding of their effects. There-
fore, as a first step to understanding the immunological
mechanism and improve the vaccine’s efficacy, we exam-
ined the effects of a non-specific immune stimulator, ger-
manium biotite, in relation to the FMD vaccine in cattle.
Results
Antibody responses to FDMV
In the analysis of the duration of antibody levels and the
secretion of IgA after FMD vaccination, the inhibition per-
centage (PI) values started to increase with the first vac-
cination, and the values were significantly increased by a
booster vaccination at 4 weeks, with the highest PI values
at 10 weeks, and this continued steadily up to 28 weeks,
regardless of whether the germanium biotite was adminis-
tered. However, the values decreased at 31 weeks in the
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quired, while the values continued at 31 weeks in the ger-
manium biotite group (Figure 1A).
FMDV-specific IgA in the saliva of the germanium
biotite group was generally higher than in the control
group, although there were no significant differences be-
tween the groups at some points during this experiment
(Figure 1B). However, IgA could not be detected in the
feces of the two groups with the kit used (data not
shown).
In the analysis of the early response of IgG, both
groups showed a steady increase in the IgG antibody
level up to 3 weeks after vaccination; after this point, the
level decreased (Figure 1C). The IgG level in the germa-
nium biotite group was higher than in the control group,
although the difference was not significant. However,
there was a significantly higher IgG antibody level at
4 weeks after vaccination when the booster vaccination
was required (p < 0.05, Figure 1C).
Virus neutralization antibody against the heterologous
FMDV strain
As shown in Table 1, the sera of the control group had a
titer of less than 16 at both points. On the other hand,
while the germanium biotite group had a VN titer of 16
or less at 20 weeks after vaccination, the VN titer in the
group was found to have increased at 31 weeks after
vaccination.
Analysis of peripheral blood mononuclear cell
subpopulation
Changes in the subpopulations of five different lympho-
cytes were analyzed based on the administration of the
germanium biotite. At 23 weeks, CD4+ lymphocytes and
MHCI+II+ cells in the germanium biotite group were
significantly higher than in the control group (p < 0.01),
while CD79a+, CD3+, and CD8+ lymphocytes exhibited
no differences between the two groups (Table 2).
Analysis of cytokine gene expression
The gene expression of IFN-γ, IL-1α, IL-1β, and IL-4
was significantly higher in the germanium biotite group
during this experiment (Figure 2). The significant high
levels of IFN-γ were determined in the germanium bio-
tite group at 3 and 8 weeks, compared to the control
(p < 0.01). In case of IL-1α and IL-1β, significant differ-
ences were observed at 3, 11, and 23 weeks and at 3, 8,
and 11 weeks, respectively (p < 0.05 and p < 0.01). The
germanium biotite group also showed significant high
levels of IL-4 at 8 and 11 weeks, compared to the con-
trol (p < 0.01). However, there were no noticeable differ-
ences in the expression levels of IL-6 and IL-10 between
the two groups although a significant difference in IL-6
expression was observed at 3 week. The germaniumbiotite feeding induced a significant increase in IFN-γ
gene expression at a relatively early stage and in IL-4 at
a late stage, while increases in IL-1α and IL-1β gene ex-
pression were observed throughout the experimental
period.
Lymphocyte proliferation
Higher lymphocyte proliferation in the germanium bio-
tite group was observed by LPS and ConA stimulation
at 23 weeks compared to the control (Figure 3A, p <
0.05).
Lysozyme activity
Of the three points at which the lysozyme activity was
measured in the serum, significantly higher lysozyme ac-
tivity was observed in the germanium biotite group at
9 weeks after starting the feeding (Figure 3B, p < 0.05).
The increase was observed at a relatively early stage after
germanium biotite feeding.
Discussion
The current FMD vaccines that are used in cattle need
to be administered every 6 months, in accordance with
the duration of the antibody, to protect against the dis-
ease [5,6,25,26]. The diversity of FMD serotypes has also
raised issues related to the efficacy of the current FMD
vaccines. Furthermore, there is considerable argument
about whether the trivalent vaccines show protective
abilities against the Andong strain through the cross-
reactivity of antibodies induced by trivalent vaccination
[24]. Based on the current knowledge of FMD vaccines,
the need for additional materials and/or methods has
been raised with a view to overcoming the problem.
Therefore, non-specific immune stimulators have re-
ceived attention as a possible solution to this issue. In
the disastrous FMD outbreak in Korea in 2010 [24],
many non-specific immune stimulators were used with-
out any scientific evidence that they would enhance pro-
tection against FMDV infection. Although non-specific
immune stimulators have been used, their efficiency is
still controversial. Therefore, we evaluated the effect of a
non-specific immune stimulator, germanium biotite, for
FMD vaccination in cattle.
Previous studies reported that a re-booster vaccination
was needed 6 months after the booster vaccination
based on the decrease of antibody titer against FMDV
[5,6,25,26]. Coinciding with these previous studies, this
study observed a decreased PI value in the control group
at 31 weeks. However, the germanium biotite group
showed a continued high level of PI value for 31 weeks.
In order to elevate the antibody level, a booster vaccin-
ation was needed 4 weeks after the first vaccination. At
that time, the germanium biotite group showed a high
level of IgG antibody compared to the control. This
Figure 1 Humoral immune responses after vaccination with Decivac FMD DOE trivalent vaccine in cattle. A. Inhibition percentage (PI) of
the antibody against FMDV serotype O in both the germanium biotite-feeding group and the non-feeding group after vaccination. The high PI
value indicates a high level of antibody titer, and the sera that showed more than 50% of the PI value were considered to be seropositive in the
ELISA assays. B. The FMDV serotype O-specific IgA response in the saliva of cattle of the germanium biotite and the control groups after vaccination
with Decivac FMD DOE trivalent vaccine. C. Induction of FMDV serotype O-specific IgG in the cattle of the germanium biotite and control groups after
vaccination with Decivac FMD DOE trivalent vaccine.
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Table 1 Virus neutralization antibody titers in sera after
vaccination
Group Samples 20 weeks 31 weeks















The selected sera were taken from the same cattle in each collection date. All
cattle were 6-month-old when the first vaccination was conducted. The sera
selected from the germanium biotite group show a higher virus neutralization
antibody titer than the control group.
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ies’ findings on the improvement of antibody production
by germanium biotite [18,19]. Furthermore, germanium
biotite feeding showed a high level of IgA in the saliva,
which could provide a beneficial effect when it comes to
protecting against FMDV infection in cattle [27]. In
addition, the IgG response suggested that the point at
which to administer the booster injection in the FMD
vaccine program for cattle is the same as indicated in
previous studies [6,26]. However, the increase in anti-
body duration suggests that the current FMD vaccine
program should be reconsidered in animals fed germa-
nium biotite. In this study, sampling of sera after
31 weeks from only first and boosting vaccinated cattle
was limited, due to national FMD control policy by which
re-booster vaccination carried out every 6 months in cattle.
The decline point of PI 6 month after booster vaccination
could not be identified. Therefore, the investigation of PITable 2 Subsets of peripheral blood mononuclear cells after m
Before administration
Control Germanium biotite
CD79a+ 8.40% (±0.17) 7.90% (±0.14)
CD3+ 59.50% (±0.49) 57.80% (±0.53)
CD4+ 14.10% (±0.72) 13.00% (±0.22)
CD8+ 12.50% (±0.74) 10.40% (±1.30)
MHC Ι+, ΙΙ+ 43.00% (±0.45) 37.50% (±0.12)
The data were expressed as mean ± standard deviation (SD) (**p < 0.01 compared tvalue changes for a longer period should be conducted in
the future study to determine the re-booster vaccination
timing.
Along with these antibody responses, a VN test was
performed using the Andong strain, which is an isolate
from the recent outbreak in Korea in 2010. Following
the vaccination, 20 weeks was the mid-point of the
period showing a high PI value and 31 weeks was the
time point that showed a difference in PI values between
the two experiment groups. To ensure the reliability of
VN test and reduce the variation, cattle in Farm B were
selected and sera of half the number of scale of each
group in Farm B were taken from the same cattle in
each collection date. As shown in Table 1, all experimen-
tal groups showed a low VN titer. These low VN titers
might be due to using the heterologous FMDV. The im-
munological relationship between the O1 Manisa vac-
cine and the Andong strains was relatively low or
moderate (r-value of approximately 0.3) [28]. A previous
study considered an r-value in the range of 0.3–1.0 as in-
dicative of reasonable levels of cross-reactivity [29].
Therefore, the low VN titers observed in this study could
be explained by the low level of the r-value between the
two strains. However, in comparison with the control
group, the increase of VN antibodies in the germanium
biotite group suggests that protectivity against FMDV in-
fection might be increased through the supplementation
of germanium biotite [3,6,9].
Although the importance of antibodies in protection
against FMDV infection is well known [3,6,9], a specific
antibody does not guarantee sterile immunity or clinical
protection against FMDV infection [9,25]. Moreover, pro-
tection against FMDV infection has been observed in the
absence of a detectable specific humoral response [30].
Therefore, it is reasonable to consider a possible protect-
ive role for innate immune responses in FMD infection
and for control of the disease [12,13,26,31]. In this study,
high lysozyme activity—indicating macrophage activity—
was observed in the germanium biotite group compared
to the control group. This result corresponds with the
findings of previous studies, which that the macrophage
activation effects of silicate (SiO2) and aluminosilicate
(Al2SiO5), which are major components of germaniumitogen stimulation
23 weeks after administration Stimulators
Control Germanium biotite
6.70% (±0.53) 4.70% (±1.01) LPS
93.50% (±0.04) 93.10% (±0.28) ConA
15.40% (±0.58) 23.80% (±0.52)** ConA
14.30% (±1.40) 10.20% (±1.21) ConA
8.80% (±0.17) 10.20% (±0.15)** ConA
o the control group at each time point).
Figure 2 Analysis of gene expression of cytokines IFN-γ, IL-1α, IL-1β, IL-4, IL-6, and IL-10. Total RNA were purified from peripheral blood
mononuclear cells separated from cattle vaccinated and fed with the germanium biotite supplement or without the supplement.
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high proliferative response of T and B lymphocytes to the
mitogen stimulation was observed in the germanium bio-
tite group compared to the control group, thereby indicat-
ing that the marker level of lymphocyte activity in the
germanium biotite group was higher than in the control
group. Through the analysis of PBMC subset stimulation
with ConA and LPS, it can be presumed that the prolifera-
tive responses of the T lymphocytes were predominately
associated with CD4+ and MHCI+ II+ cells, as the CD4+
and MHCI+ II+ cells were significantly increased at
23 weeks after stimulation with ConA. The important roleof CD4+ T-cells in the induction of the antibody response
in ruminants following infection or vaccination with a
virus or a viral peptide has been demonstrated [11,12].
Furthermore, MHC II–restricted T-cells (CD4) play an
important role in the immune responses to the FMDV
antigen and the activation of macrophages [31]. These re-
sults show the increase of activation markers for innate
immune responses associated with cell-mediated immun-
ity in the germanium biotite group. In addition, previous
studies reported that the cross-reactivities against a heter-
ologous virus were mainly induced by T-cell responses to
FMDV vaccination [13]. Therefore, it could be postulated
Figure 3 Proliferation of peripheral blood mononuclear cells
(PBMCs) and lysozyme activity of sera. A. PBMCs were separated
from the vaccinated cattle that were fed with the germanium biotite
supplement or without the supplement at 0 and 23 weeks. The
proliferation of the PBMCs was estimated after stimulation with LPS
or ConA. B. The lysozyme activities of the sera from the vaccinated
cattle that were fed with the germanium biotite supplement or
without the supplement were measured based on the dissolution
ability against Micrococcus lysodeikticus.
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germanium biotite group compared to the control might
result from enhanced T-cell responses due to germanium
biotite feeding.
The increase of the expression of the IFN-γ, IL-1α, IL-
1β, and IL-4 genes in the germanium biotite group was
in agreement with the results that demonstrated the ac-
tivation of immune cells associated with cell-mediated
immune responses. The increase of the IFN-γ expression
level and the CD4+ T-cell subpopulation in our results is
closely correlated with a previous report that indicated
that CD4+ T-cells were the major proliferating pheno-
type and IFN-γ producing cells [12]. The induction of
IFN-γ expression has been observed in antigen-specific
T-cell activation [32], MHC II–restricted T-cells (CD4)
[5], and activation of macrophages [31]. This immune
cell activation induced by IFN-γ expression could also
be observed in our results through the increases in the
CD4+ and MHCI+ II+ cell subpopulations, lysozymeactivity, and lymphocyte proliferation level. In addition,
the antiviral activity of IFN-γ against FMDV contributed
to the control of FMDV replication and the spread of
the virus within the host via activation of NK cells and
macrophages [33]. IL-1α and IL-1β are mainly produced
in activated macrophages and promote Th2 immune
cells, which represent the major source of IL-4 [34]. IL-4
also promotes Th2 cell growth and enhances MHC II
expression in B-cells [34]. These results suggest that ger-
manium biotite induces Th1 and Th2 responses through
the activation of macrophages and CD4+ class II MHC–
restricted T-cells [1,34]. Considering these results, it can
be presumed that supplementation of germanium biotite
may activate cell-mediated immunity, thereby enhancing
the induction of the immune responses by FMD vaccin-
ation and the protectivity against FMDV infection. How-
ever, the effects of germanium biotite on T-cell activation
through FMDV specific T-cell responses could not be in-
vestigated. Therefore, an inquiry on the effects of germa-
nium biotite on immune responses to FMDV vaccination
through a comparative study of T-cell responses using
FMDV antigen were needed to evaluate the specific effects
in a further research.
In addition, a large difference in the appearance of the
MHC II subpopulation was observed in the experiment
cattle between two time points, before and after the ad-
ministration of the germanium biotite. Previous studies
showed that the MHC II subpopulation in the PBMCs
of Holstein at 5–7 and 15–16 months could be esti-
mated at about 32.2% and 10.7%, respectively [35,36].
Based on these reports, it can be presumed that the sig-
nificant difference in this study could be caused by the
age change in the experiment calves.
Conclusions
The results of this study suggest an enhancement of the
immune responses to FMD vaccination through the sup-
plementation of dietary germanium biotite such as IgG,
IgA, and VN antibodies. It can be presumed that these en-
hancements are induced by the immunostimulating effects
of the germanium biotite, including the activation of mac-
rophages and CD4+ class II MHC–restricted cells, as well
as the induction of cytokines, which can activate Th1 and
Th2 immune cells. In conclusion, the findings of this study
indicate that dietary germanium biotite could be used to
improve the efficacy of the FMD vaccine.
Methods
Experimental animals and vaccination
This experiment was carried out with 89 cattle from 6–8
months in age (Korean Native Cattle) at three different
farms, which were located in different provinces in
Korea. Forty-five cattle were raised with feed supple-
mented with 0.5% germanium biotite (SoltoB, Seobong
Jung et al. BMC Veterinary Research 2014, 10:179 Page 8 of 10
http://www.biomedcentral.com/1746-6148/10/179BioBestech Co, Seoul, Korea; germanium biotite group)
from 1 week before vaccination to the end of the experi-
ment, while the rest were raised without supplementation
(control group). Control and germanium biotite groups
were arranged at each farm (Table 3). All the cattle were
intramuscularly vaccinated with 2 ml of Decivac FMD
DOE trivalent vaccine (InterVet, Germany). A booster
vaccination was given 4 weeks after the first vaccination,
according to the national vaccination policy of Korea.
Samples of blood, saliva, and feces were collected before
vaccination and up to 6 months after the second vaccin-
ation. Feces and saliva were collected by swabbing with a
cotton swab. Bleeding was carried out from the jugular
vein. Sera were collected and stored at −20°C until use
after inactivation at 56°C for 30 min. The cotton swabs
were immersed in 1 ml of PBS for 1 h at 4°C, and the su-
pernatants were collected after centrifugation at 1,500 × g
for 15 min at 4°C; the supernatants were stored at −20°C
and used as samples for the ELISA analysis of FMDV-
specific IgA.
The germanium biotite consisted of silicon dioxide
(61.90%), aluminum dioxide (23.19%), iron oxide (3.97%),
sodium oxide (3.36%), calcium oxide (<2%), magnesium
oxide (<2%), titanium oxide (<2%), and 36 ppm germa-
nium. All procedures in the animal experiment in this
study were approved by the Institution Animal Care and
Use Committee (IACUC) of Seoul National University
(SNU-111210-1).Measurement of antibody against FMDV
The antibody titers against FMDV were measured using
the PrioCHECK FMDV type O ELISA kit (Prionics,
Switzerland) following the manufacturer’s protocols. The
serotype O antibody titer using this ELISA kit is the cri-
terion for assessing seropositivity in the national policy
of Korea. The antibody titer against FMDV was indi-
cated by the PI value. The high PI value presents a high
level of antibody titer, and the sera that showed more
than 50% of the PI value were considered to be seroposi-
tive in the ELISA assays. FMDV-specific IgG in theTable 3 Experiment design for grouping, sampling, and analy
Farms Number of cattle Samples Analysis
Control Germanium biotite
A 26 22 Serum, saliva, feces Inhibitio
B 13 18 Serum, saliva, feces Inhibitio
virus neu
C 5 5 Serum, saliva, feces, PBMC Inhibitio
PBMC (p
Among 89 cattle at 6–8 months of age, 45 cattle were raised with feeds supplemen
of experiment (germanium biotite group) and the rest of them were raised withoutserum were measured using the PrioCHECK FMDV type
O ELISA kit (Prionics) with 1:40 diluted serum and
horseradish peroxidase (HRP)-conjugated sheep anti-
bovine IgG (Bethyl, USA). In addition, FMDV-specific
IgA in the saliva and feces was measured using the Prio-
CHECK FMDV type O ELISA kit (Prionics) with 1 x
samples extracted by PBS from cotton swabs and HRP-
conjugated rabbit anti-bovine IgA (Bethyl). All proce-
dures for detecting FMDV-specific IgG and IgA followed
the manufacturer’s protocols with a 1:3,000 dilution of
each immunoglobulin-specific conjugate.
Analysis of VN antibody titer
The VN titer was measured in eight randomly selected
sera from the germanium biotite and seven sera from the
control groups of Farm B at 20 and 31 weeks after vaccin-
ation (Tables 1 and 3). Fifty microliters of twofold serially
diluted bovine sera were reacted with 50 μl of the FMDV
Andong strain (100TCID50), a serotype O FMDV Korean
isolate from the 2010 outbreak, at 37°C for 1 h. After incu-
bation, 50 μl of complete Dulbecco’s Modified Eagle
Medium (Gibco, USA) with 5% fetal bovine serum con-
taining 1 × 104 LFBK cells/ml was added to the reaction
mixture. After incubation of the reaction mixtures at 37°C
for 48 h, the VN titer was determined as the final dilution
of serum showing no cytopathic effect.
Analysis of PBMC subsets
Among the 89 cattle, analysis of the peripheral lymphocyte
profiles was conducted with ten Korean native cattle
(IACUC permission no. SNU-111210-1). Five of them were
fed with a commercial feed supplemented with 0.5% ger-
manium biotite (germanium biotite group), while the rest
were fed without the supplement (control group). PBMCs
were cultured from the heparinized whole blood of the ex-
periment cattle using the Histopaque®-1077 Hybri-Max™
(Sigma, USA) system, as described by the manufacturer.
The PMBCs were then stimulated with DPBS (Gibco),
ConA (5 g/ml, Sigma) for CD3, CD4, CD8, and MHC I
and II and LPS (5 g/ml, Sigma) for CD79a staining for 96 hsis
of
n percentage, ELISA for antibody levels (IgG and IgA), lysozyme activity
n percentage, ELISA for antibody levels (IgG and IgA), lysozyme activity,
tralization test
n percentage, ELISA for antibody levels (IgG and IgA), lysozyme activity,
henotype, cytokines, proliferation)
ted with 0.5% germanium biotite from 1 week before vaccination to the end
supplementation (control group).
Table 4 Antibodies used to detect the cell surface markers
Target Antibody Company
CD79a PE-conjugated mouse anti-bovine CD79a Abcam, UK
CD3 FITC-conjugated hamster anti-bovine CD3 Abcam
CD4 PE-conjugated mouse anti-bovine CD4 US Biological, USA
CD8 PE-conjugated mouse anti-bovine CD8 LifeSpan BioSciences, USA
MHC Ι FITC-conjugated mouse anti-bovine MHC Ι Novus Biological, USA
MHC ΙΙ Mouse anti-bovine MHC ΙΙa Abcam
Fc receptor blocking Polyclonal mouse IgG fraction Abcam
Monoclonal Armenian hamster IgG fraction Abcam
aMouse anti-bovine MHC ΙΙ antibody was conjugated with PE using an EasyLink B-Phycoerythrin conjugation kit (Abcam).
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stimulation with mitogens. The procedures for cell fixation
and antibody reaction to detect the cell markers were per-
formed as previously reported [37] using the DPBS with
0.2% Tween® 20 (Sigma) as the permeabilisation solution.
To prevent a non-specific reaction of the Fc receptor with
the detection antibodies, the fixed cells were reacted with
normal Ig from the antibody-producing host for 10 min
and reacted with fluorescein isothiocyanate (FITC) or
phycoerythrin (PE)-conjugated cell surface marker detec-
tion antibodies. After the reaction, the number of cells
reacting with the FITC or PE conjugate was analyzed using
Flow cytometric analysis (BD, USA). The monoclonal anti-
bodies used for the staining of the cells surface markers are
listed in Table 4.
Analysis of cytokine gene expression in PBMC
Total RNAs were extracted from PBMCs with the RNeasy
mini kit (Qiagen, USA), and cDNAs were synthesized with
the reverse transcription kit (Qiagen). The relative expres-
sion levels of IFN-γ, IL-1α, IL-1β, IL-4, IL-6, and IL-10
were quantitated using the Rotor-Gene SYBR Green PCR
kit (Qiagen) and Rotor-Gene Q (Qiagen), as previously re-
ported [38]. The expression levels were normalized by β-
actin expression using the 2-ΔΔCT method [39].
Analysis of PBMC proliferation
A lymphocyte proliferation assay was conducted with the
PBMCs collected from the experiment cattle. Ninety mi-
croliters of PBMCs (5 × 106 cells/ml) in a 96-well plate
were incubated with ConA (5 μg/ml) and LPS (5 μg/ml) at
37°C for 96 h in a 5% CO2 atmosphere. Absorbance at
560 nm was measured 2 h after the addition of 10 μl of
10× Prestoblue (Invitrogen, USA). Proliferation of the
PBMCs was compared based on this absorbance.
Analysis of lysozyme activities
Lysozyme activities in the serum were measured based on
the dissolution ability against Micrococcus lysodeikticus(Sigma) [40]. The activity was calculated based on the
standard curve generated from the serially diluted lyso-
zyme solution.
Statistical analysis
The data were expressed as mean ± standard deviation
(SD). A student’s t-test and repeated measures of ANOVA
were performed for statistical analysis of the data. All stat-
istical analyses of data were carried out using SPSS version
19.0 software (SPSS, USA). A probability value of p < 0.05
was considered significant.
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